4.53
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.13
Offen:
$4.24
24-Stunden-Volumen:
5.26M
Relative Volume:
0.60
Marktkapitalisierung:
$813.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.86M
KGV:
-18.43
EPS:
-0.2458
Netto-Cashflow:
$-28.39M
1W Leistung:
+13.11%
1M Leistung:
-18.08%
6M Leistung:
+139.68%
1J Leistung:
+335.58%
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Firmenname
Sellas Life Sciences Group Inc
Sektor
Branche
Telefon
(646) 200-5278
Adresse
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
SLS
Sellas Life Sciences Group Inc
|
4.53 | 741.68M | 0 | -26.86M | -28.39M | -0.2458 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Eingeleitet | Oppenheimer | Outperform |
| 2018-04-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Hochstufung | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
SELLAS Life Sciences Group Stock Jumps 9.5% - National Today
Stock Report: Will SELLAS Life Sciences Group Inc benefit from green energy policies2026 Review & Safe Swing Trade Setup Alerts - baoquankhu1.vn
FRA:RXK3 PB Ratio: 9.04 — 66% Above Median - gurufocus.com
SELLAS Life Sciences Group (SLS) price target increased by 26.83% to 8.84 - MSN
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN
SLS stock rallies ahead of AML trial readout — 'Pharma Bro' Martin Shkreli says he's still 'very bearish,' predicts drug will fail - MSN
SELLAS Life Sciences (SLS) to present SLS009 data at AACR 2026 - MSN
SLS Technical Analysis & Stock Price Forecast - Intellectia AI
SELLAS Life Sciences Group Stock Price Drops 7.7% - National Today
Gainers Report: Whats next for SELLAS Life Sciences Group Inc stock2026 Highlights & Low Risk Growth Stock Ideas - baoquankhu1.vn
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 7.7%Here's Why - MarketBeat
SLS Forecast, Price Target & Analyst Ratings | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
Why SELLAS Life Sciences Group (SLS) Is Down 8.3% After US$150 Million ATM Offering News - simplywall.st
SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum - MSN
Sellas Life Sciences Secures Shelf Registration to Bolster Financial Flexibility - timothysykes.com
Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade - MSN
A Look At SELLAS Life Sciences Group (SLS) Valuation After SLS009 Data And New Equity Offering Plans - simplywall.st
SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026 - Insider Monkey
MACD Signal: Is SELLAS Life Sciences Group Incs ROIC above industry average2026 Price Targets & Smart Investment Allocation Tips - baoquankhu1.vn
Vanguard (SLS) files amendment showing 0% beneficial ownership (warrants disclosed) - Stock Titan
5 Popular Penny Stocks on Robinhood to Buy - Insider Monkey
All you need to know about SELLAS Life Sciences Group, Inc. (SLS) rating upgrade to buy - MSN
All Essential Information Regarding SELLAS Life Sciences Group, Inc. (SLS) Rating Raised to Buy - Bitget
All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy - Yahoo Finance
SELLAS Life Sciences Group Inc (SLS) Stock News & Articles - 24/7 Wall St.
SLS Stock Jumps After Merck's Tern Deal Sparks Buyout Buzz In Blood-Cancer Space: Retail Bets On This Big Pharma Suitor - Stocktwits
SLS Eyes New Capital Streams with Securities Shelf Registration - StocksToTrade
SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 8.5%Here's Why - MarketBeat
SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths - AOL.com
Sellas Life Sciences: New Price Targets Signal Optimism Amid Clinical Progress - stockstotrade.com
SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 12.9%Here's Why - MarketBeat
Dagco Inc. Purchases Shares of 577,540 SELLAS Life Sciences Group, Inc. $SLS - marketbeat.com
SELLAS Life Sciences Group, Inc.(NasdaqCM:SLS) added to S&P Biotechnology Select Industry Index - marketscreener.com
Penny Stocks To ResearchMarch 22nd - MarketBeat
Assessing SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Run - Yahoo Finance
Penny Stocks To Watch NowMarch 21st - MarketBeat
BUY Rating on SELLAS: Pivotal REGAL Phase 3 Progress, Expanding AML Pipeline, and Cash Runway into 2027 Support Upside Potential - TipRanks
Investment Review: Whats the beta of SELLAS Life Sciences Group Inc stockMarket Performance Recap & High Return Trade Opportunity Guides - baoquankhu1.vn
SELLAS Life Sciences’ AML Pipeline Adds Key Clinical Checkpoints For Investors - simplywall.st
SELLAS Life Sciences Group, Inc.: Fundamental Analysis and Financial Ratings | | US81642T2096 - marketscreener.com
Form S-3ASR Sellas Life Sciences Group Inc For: 20 March - Investing.com
SELLAS (NASDAQ: SLS) registers shelf and $150M ATM with TD Cowen - Stock Titan
SLS Stock In Focus As Alliance Global Sees 92% Upside Following AML Trial Updates - Stocktwits
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up on Earnings Beat - MarketBeat
Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sellas Life Sciences Group Inc-Aktie (SLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| VAN NOSTRAND ROBERT L | Director |
Jun 12 '25 |
Buy |
1.48 |
10,000 |
14,800 |
20,400 |
| Wasman Jane | Director |
May 30 '25 |
Buy |
1.69 |
20,000 |
33,800 |
30,400 |
| Kalin Katherine Bach | Director |
May 22 '25 |
Buy |
1.80 |
20,000 |
36,000 |
41,000 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):